Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Angelini

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

- PMLiVE

Ariad gets EU green light for leukaemia drug Iclusig

EC approves drug in two forms of the blood cancer

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

Jonathan Dickinson joins Ariad from BMS

Will lead launch of chronic myeloid leukaemia treatment Iclusig

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

Ariad’s lung cancer drug impresses at ESMO

Early stage trials demonstrate potential in hard-to-treat patients

EMA grants accelerated assessment to Ariad’s leukaemia drug

Could cut months off approval decision for ponatinib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links